›› 2013, Vol. 33 ›› Issue (1): 104-.doi: 10.3969/j.issn.1674-8115.2013.01.021

• 综述 • 上一篇    下一篇


张勰义, 宋少莉, 黄 钢   

  1. 上海交通大学 医学院附属仁济医院核医学科, 上海 200127
  • 出版日期:2013-01-28 发布日期:2013-02-06
  • 通讯作者: 宋少莉, 电子信箱: shaoli-song@163.com;黄 钢, 电子信箱: huang2802@163.com。
  • 作者简介:张勰义(1987—), 男, 住院医师, 硕士生;电子信箱: rabbitzxy@163.com。
  • 基金资助:


Research progress of imaging receptor tyrosine kinase targeted drugs by radionuclide

ZHANG Xie-yi, SONG Shao-li, HUANG Gang   

  1. Department of Nuclear Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China
  • Online:2013-01-28 Published:2013-02-06
  • Supported by:

    National Natural Science Foundation of China, 81101073; Shanghai Pujiang Talent Plan



关键词: 跨膜酪氨酸激酶受体, 酪氨酸激酶受体, 酪氨酸激酶抑制剂, 核素显像, 反应监测, 靶向药物


Transmembrane receptor tyrosine kinase signalling triggers cell proliferation, apoptosis suppression and neovasculature recruitment. Transmembrane receptor tyrosine kinases are overexpressed in many malignancies, which have become the molecular targets for an increasing number of anticancer drugs. For example, monoclonal antibodies and small-molecule tyrosine kinase inhibitors have been clinically proved to boost the therapeutic effect and increase the survival of patients. However, the targeted drugs are clinically limited by specific target and high price, and the early monitoring of therapeutic effects of targeted drugs is important for the design of clinical regimen and reduction of adverse effects and medical expense. The imaging of receptor tyrosine kinase targeted drugs by radionuclide has been clinically employed in the monitoring of therapeutic effects of targeted drugs, and the research progress of this application is reviewed in this paper.

Key words: transmembrane receptor tyrosine kinases, receptor tyrosine kinases, tyrosine kinase inhibitors, radionuclide, response monitor, targeted drugs